Registry update — unassessed
Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial
Trial registry update: COMPLETED. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Mar 13, 2013 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- This is a protocol abstract with no outcome data reported, so no effects can be established
- Gene expression changes in blood cells do not establish clinical benefits or effects on actual aging or lifespan
- The study does not report sample size, effect sizes, or statistical significance for any measured outcomes
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 2 months
- Population
- Pre-diabetic individuals
- Primary outcome
- Expression of longevity genes SIRT1, p66Shc, p53 and mTOR in peripheral blood mononuclear cells (PBMCs)
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Padova
- Published
- Mar 13, 2013
Sources
Primary source
- University of Padova ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This clinical trial aims to describe the effects of the AMPK pathway on longevity genes and inflammation in the setting of pre-diabetes in vivo and in vitro.
To this end, the investigators will compare treatment with metformin (500 mg t.i.d) for 2 months, versus placebo in pre-diabetic subjects.
The investigators will assess expression of longevity genes SIRT1, p66Shc, p53 and mTOR in peripheral blood mononuclear cells (PBMCs) ex vivo.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.